BioCentury | Sep 16, 2020
Product Development

Pace of Monjuvi’s growth may dictate how quickly MorphoSys can rebuild its pipeline

MorphoSys’ first marketed therapeutic, Monjuvi, has the makings of a blockbuster, but the company and partner Incyte will need to execute on the drug’s launch and planned label expansions to generate the...
BioCentury | Apr 11, 2020
Management Tracks

Harpal Kumar named president of Grail Europe; plus Notable, Oncoceutics, ReAlta, Parker Institute

Grail Inc. hired Sir Harpal Kumar as president of the liquid biopsy company’s Europe operations. He was SVP and head of innovation in Europe, the Middle East and Africa at Johnson & Johnson (NYSE:JNJ) and...
BioCentury | Aug 22, 2019
Clinical News

After neurodegeneration miss, Retrophin looks to rebound with renal program

With plans to discontinue fosmetpantotenate after its Phase III miss, Retrophin President and CEO Eric Dube believes the $425 million with which it ended last quarter is enough to bring its remaining clinical candidate to...
BioCentury | Jun 19, 2019
Financial News

Coenzyme A company Comet debuts with $28.5M series A

Led by former Syntimmune CEO David de Graaf, Comet launched Wednesday with $28.5 million in series A funding to develop precursors of coenzyme A to treat metabolic, immune and neurological disorders that involve dysregulated coenzyme...
BioCentury | Jun 1, 2019
Product Development

ASCO 2019 abstracts show solid tumor race heating up among bispecifics and CAR Ts

While strong progress in CAR T therapies will again feature at this year’s ASCO meeting, bispecific antibodies are having a moment -- making more inroads into solid tumors than CAR Ts and branching out via...
BioCentury | Nov 6, 2018
Distillery Therapeutics

Neurology

INDICATION: Neurology In vitro , cell culture and mouse studies identified a PANK3 activator that could help treat pantothenate kinase-associated neurodegeneration (PKAN), which is caused by PANK2 deficiency and leads to low Coenzyme A levels in...
BioCentury | Aug 29, 2018
Distillery Techniques

Imaging; other

TECHNOLOGY: MRI; computational models A computational model based on functional MRI and clinical presentation could predict whether unconscious brain injury patients will recover consciousness within 12 months. The model incorporates functional MRI imaging, injury etiology,...
BioCentury | Jun 13, 2018
Company News

BridgeBio launches rare genetic disorder subsidiary

BridgeBio Pharma LLC (Palo Alto, Calif.) launched another subsidiary this week, forming CoA Therapeutics Inc. to develop small molecules which increase coenzyme A levels to treat rare genetic disorders. CoA CEO Shafique Virani told BioCentury...
BioCentury | Nov 14, 2017
Distillery Techniques

Assays and screens; biomarkers

TECHNOLOGY: Diagnostic assays; tissue markers Profiling a subset of gut microbiota could help diagnose atherosclerotic cardiovascular disease. Metagenomic analysis of fecal samples from 218 patients with stable angina, unstable angina or MI, and 187 healthy...
BioCentury | Oct 24, 2017
Distillery Techniques

Disease models

TECHNOLOGY: Cell models A biobank of insertional mutagenesis-derived haploid mouse ESCs could be used to link genes to disease-related phenotypes in homogeneous cell populations. The biobank consists of over 100,000 haploid mouse ESCs with genetically...
Items per page:
1 - 10 of 368